+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years - 70Years
All Genders
ID06760364

Phase I Study of CHT102 for Mesothelin-Positive Advanced Pancreatic Cancer with Arterial Infusion Treatment

Led by Tianjin Medical University Cancer Institute and Hospital · Updated on 2025-04-10

21

Participants Needed

1

Research Sites

626 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to evaluate the safety and effectiveness of mesothelin-targeting UCAR-T cells called CHT102 in adults with mesothelin-positive advanced pancreatic cancer who have not responded to or cannot tolerate standard treatments. It is a phase 1, open-label study conducted by Tianjin Medical University Cancer Institute and Hospital to better understand this treatments potential in this serious condition. Participants will receive CHT102 through arterial infusion. The study includes a dose escalation phase with three planned dose groups, followed by a dose expansion phase after a safety review committee evaluates available safety, pharmacokinetics, and preliminary efficacy data. This single-arm study does not include a placebo or comparator group. Throughout the study, participants will be closely monitored for safety and tolerability over two years. Researchers will assess tumor response using measures such as objective response rate and disease control rate at four weeks and overall, progression-free survival over two years, and overall survival over three years. Pharmacokinetics and pharmacodynamics will be evaluated for six months to understand how the treatment behaves in the body. The total duration of participant involvement will span several years to carefully track outcomes and safety.

CONDITIONS

Brief Title

A Clinical Study of CHT102 in MSLN-Positive Advanced Pancreatic Cancer

Research Team

J

Jihui Hao, Ph.D

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here